Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WITH HIGH-DOSE BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT):Z BEAM 2

    Summary
    EudraCT number
    2007-000270-23
    Trial protocol
    BE  
    Global end of trial date
    29 Jan 2014

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Oct 2017
    First version publication date
    14 Oct 2017
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    Z BEAM 2
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00689169
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    LYSA
    Sponsor organisation address
    CH Lyon Sud - Service d’Hématologie - Bâtiment 1F - 3ème étage , Pierre-Bénite Cedex, France, 69495
    Public contact
    Christine Stephan, LYSARC, +33 4 72 66 93 33,
    Scientific contact
    Christophe Fruchart, LYSA, fruchart-c@chu-caen.fr
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    28 Jun 2012
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Jan 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the efficacy and the safety of a preparative regimen utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to 65 years CD20 positive Diffuse Large B-Cell lymphoma with poor prognosis PRIMARY ENDPOINT: Event free survival (EFS) at 2 years: events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy.
    Protection of trial subjects
    Supportive treatments administered according to the standard use of each center. Treatment for progression/relapse administered at the discretion of treating physician.
    Background therapy
    No background therapy.
    Evidence for comparator
    No comparator.
    Actual start date of recruitment
    21 Aug 2007
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Scientific research
    Long term follow-up duration
    10 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 7
    Country: Number of subjects enrolled
    France: 66
    Country: Number of subjects enrolled
    Switzerland: 2
    Worldwide total number of subjects
    75
    EEA total number of subjects
    73
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    75
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment period : from 21/08/2007 to 18/12/2008. Patients recruited in France, Belgium and Switzerland.

    Pre-assignment
    Screening details
    pathologically proven large B-Cell lymphoma CD20 positive (without transformation from low grade), in CR or PR after induction treatment (R CHOP like or R ACVBP), eligible for autologous stem cell transplantation 75 patient included

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Z-BEAM + ASCT
    Arm description
    Conditioning regiment rituximab + ZBEAM followed by ASCT
    Arm type
    Experimental

    Investigational medicinal product name
    Rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    250 mg/m² administered at D-21 and D-14 before ASCT

    Investigational medicinal product name
    90Y ibritumomab tiuxetan
    Investigational medicinal product code
    Other name
    Zevalin
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    0,4 mCi/kg administered at D-14 before ASCT

    Investigational medicinal product name
    Carmustine
    Investigational medicinal product code
    Other name
    BCNU
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    300 mg/m² administered at D-6 before ASCT

    Investigational medicinal product name
    etoposide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    100 mg/m²/12h administered from D-6 to D-3 before ASCT

    Investigational medicinal product name
    cytarabine
    Investigational medicinal product code
    Other name
    aracytine
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    200 mg/m²/12h administered from D-6 to D-3 before ASCT

    Investigational medicinal product name
    melphalan
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    140 mg/m² administered at D-2 before ASCT

    Number of subjects in period 1
    Z-BEAM + ASCT
    Started
    75
    Enrollment of patient
    75
    Study treatment
    73
    ASCT
    71
    Completed
    71
    Not completed
    4
         No study treatment received
    2
         Lack of efficacy
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    -

    Reporting group values
    Overall trial Total
    Number of subjects
    75 75
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        median (full range (min-max))
    49 (19 to 64) -
    Gender categorical
    Units: Subjects
        Female
    43 43
        Male
    32 32
    Performance status (ECOG) at baseline
    Units: Subjects
        00
    24 24
        01
    27 27
        02
    16 16
        03
    7 7
        04
    1 1
    Age
    Units: Subjects
        <= 60
    68 68
        > 60
    7 7
    Ann Arbor Stage
    Units: Subjects
        Stage 1
    1 1
        Stage 2
    4 4
        Stage 3
    12 12
        Stage 4
    58 58
    B symptoms
    Units: Subjects
        No
    35 35
        Yes
    40 40
    LDH
    Units: Subjects
        <= 1N
    7 7
        > 1N
    68 68
    Age-ajusted IPI
    Units: Subjects
        00
    0 0
        01
    5 5
        02
    53 53
        03
    17 17
    Number of extranodal sites involved
    Units: Subjects
        <= 1
    31 31
        >1
    44 44
    IPI
    Units: Subjects
        01
    1 1
        02
    27 27
        03
    31 31
        04
    15 15
        05
    1 1
    Bone Marrow biopsy at dignosis
    Units: Subjects
        Not involved
    56 56
        Involved
    15 15
        Not done
    4 4
    PET Scan at diagnosis
    Units: Subjects
        Positive
    53 53
        Not done
    22 22
    Performance Status (ECOG) at registration
    Units: Subjects
        00
    50 50
        01
    24 24
        02
    1 1
    Response after induction treatment
    Units: Subjects
        COMPLETE RESPONSE
    30 30
        UNCONFIRMED COMPLETE RESPONSE
    33 33
        PARTIAL RESPONSE
    12 12
    Bone marrow biopsy after induction
    Units: Subjects
        Not involved
    25 25
        Not done
    50 50
    PET scan after induction
    Units: Subjects
        Negative
    54 54
        Positive
    21 21
    Induction treatment - type of chemotherapy
    Units: Subjects
        R-CHOP like
    36 36
        R-ACVBP like
    39 39
    Weight
    Units: kg
        median (full range (min-max))
    63 (45 to 100) -
    Height
    Units: cm
        median (full range (min-max))
    170 (140 to 195) -
    Body area
    Units: m²
        median (full range (min-max))
    1.74 (1.44 to 2.29) -
    Number of extranodal sites at diagnosis
    Units: number
        median (full range (min-max))
    2 (0 to 9) -
    Number of sites used for response evaluation at diagnosis
    Units: number
        median (full range (min-max))
    2 (1 to 6) -
    Number of sites used for response evaluation at registration
    Units: number
        median (full range (min-max))
    2 (1 to 6) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Z-BEAM + ASCT
    Reporting group description
    Conditioning regiment rituximab + ZBEAM followed by ASCT

    Subject analysis set title
    Safety population
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    The safety population comprises all patients registred and having received the dose of study treatment (Zevalin).

    Subject analysis set title
    Patient with transplantation
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    All patients registred and having received ZBEAM and transplantation.

    Primary: Event Free survival from ASCT

    Close Top of page
    End point title
    Event Free survival from ASCT [1]
    End point description
    Event free survival (EFS) at 2 years: events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy. Event-Free survival is measured both from date of inclusion and from date of transplantation to date of first event.
    End point type
    Primary
    End point timeframe
    24 months after ASCT
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Since there is only one treatment arm, it is not possible to indicate comparative statistical analysis as required by EudraCT system.
    End point values
    Patient with transplantation
    Number of subjects analysed
    71
    Units: percent
        number (confidence interval 5%)
    78.8 (67.4 to 86.7)
    No statistical analyses for this end point

    Secondary: Overall Response Rate

    Close Top of page
    End point title
    Overall Response Rate
    End point description
    Overall response rate (ORR) (complete response CR and partial response PR) at day 100 after ASCT. Overall response rate (ORR) will be defined as defined according to Cheson 1999 criteria. Patients without response assessment are considered as non-responder.
    End point type
    Secondary
    End point timeframe
    Overall Response rate at D100 after ASCT or at withdrawal.
    End point values
    Safety population
    Number of subjects analysed
    73
    Units: percent
        number (confidence interval 5%)
    83.6 (73 to 91.2)
    No statistical analyses for this end point

    Secondary: Overall survival

    Close Top of page
    End point title
    Overall survival
    End point description
    Overall survival is measured from the date of inclusion or from evaluation at month 3 post-transplant to the date of death, irrespective of the cause. Patients who have not died at the time of analysis will be censored at the most recent date they were known to be alive or at the stopping date if the most recent date is later.
    End point type
    Secondary
    End point timeframe
    Overall survival 24 months after ASCT.
    End point values
    Patient with transplantation
    Number of subjects analysed
    71
    Units: percent
        number (confidence interval 5%)
    83.1 (72.1 to 90)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All Adverse Events (AE) occurring during the treatment period will be recorded until 100 days after the end of the last dose of treatment
    Adverse event reporting additional description
    Due to the expected toxicity of these treatments, only grade 3,4 and 5 toxicities (Common Terminology Criteria for Adverse Events (CTCAE) v3.0) or grade 2 for infections, and toxicities (grade 1 to 5) related to a Serious Adverse Event, must be reported as “Adverse Event”.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    10.0
    Reporting groups
    Reporting group title
    Safety population
    Reporting group description
    The safety population comprises all patients registred and having received the dose of study treatment (Zevalin).

    Serious adverse events
    Safety population
    Total subjects affected by serious adverse events
         subjects affected / exposed
    18 / 73 (24.66%)
         number of deaths (all causes)
    14
         number of deaths resulting from adverse events
    1
    Cardiac disorders
    Myopericarditis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Leukopenia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Lung disorder
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    Acute respiratory distress syndrome
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal failure acute
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Septic shock
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    1 / 1
    Arthritis bacterial
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Herpes virus infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Herpes oesophagitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterocolitis fungal
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Bronchopulmonary aspergillosis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Safety population
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    68 / 73 (93.15%)
    General disorders and administration site conditions
    Mucosal inflammation
         subjects affected / exposed
    35 / 73 (47.95%)
         occurrences all number
    35
    Asthenia
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences all number
    3
    Pyrexia
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Fatigue
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Respiratory, thoracic and mediastinal disorders
    Lung disorder
         subjects affected / exposed
    4 / 73 (5.48%)
         occurrences all number
    4
    Acute respiratory distress syndrome
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Investigations
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Liver function test abnormal
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Cardiac disorders
    Myopericarditis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    39 / 73 (53.42%)
         occurrences all number
    39
    Neutropenia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Leukopenia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Thrombocytopenia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Eye disorders
    Keratitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Diplopia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    5 / 73 (6.85%)
         occurrences all number
    5
    Anal inflammation
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Dysphagia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Enterocolitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Enteritis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Abdominal pain upper
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    renal failure acute
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Infections and infestations
    Infection
         subjects affected / exposed
    8 / 73 (10.96%)
         occurrences all number
    8
    Neutropenic infection
         subjects affected / exposed
    5 / 73 (6.85%)
         occurrences all number
    5
    Urinary tract infection
         subjects affected / exposed
    5 / 73 (6.85%)
         occurrences all number
    5
    Diarrhoea infectious
         subjects affected / exposed
    4 / 73 (5.48%)
         occurrences all number
    4
    Herpes zoster
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences all number
    3
    Staphylococcal infection
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences all number
    3
    Rhinitis
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences all number
    3
    Tooth abscess
         subjects affected / exposed
    3 / 73 (4.11%)
         occurrences all number
    3
    Pneumonia
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Escherichia infection
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Septic shock
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Staphylococcal sepsis
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Escherichia urinary tract infection
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Bronchitis
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Herpes oesophagitis
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Cystitis
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Arthritis bacterial
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Oral candidiasis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Ear infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Enterococcal infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Genital infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Oral fungal infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Klebsiella infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Proteus infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Enterocolitis infectious
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Herpes virus infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Respiratory tract infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Enterocolitis fungal
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Candidiasis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Bacteremia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Pneumocystis jirovecii pneumonia
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Pharyngitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Fungal infection
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Pseudomonal sepsis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Bronchopulmonary aspergillosis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Sinusitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Streptococcal sepsis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Nasopharyngitis
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Anorexia
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Hypokalaemia
         subjects affected / exposed
    2 / 73 (2.74%)
         occurrences all number
    2
    Dehydration
         subjects affected / exposed
    1 / 73 (1.37%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/25072780
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:55:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA